肝腎綜合征治療措施的臨床證據_《中國循證醫學雜志》

作者：

柳飛 ¹ ,  李峻 ²

1.四川大學華西醫院腎內科(成都610041)2.四川大學華西醫院老年科;

關鍵詞：

肝腎綜合征循證治療

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　對肝腎綜合征（hepatorenal syndrome, HRS）治療的相關臨床研究證據進行評價。
方法　運用循證醫學的基本原理和方法系統檢索HRS治療的相關臨床研究證據，并對證據質量進行評價。
結果　擴容、縮血管藥物及改善腎血流量的血管活性藥物、經頸靜脈肝內門體分流術、肝移植是目前臨床治療HRS的常用方法，有一定治療作用。
結論　HRS是終末期肝病的常見并發癥，預后極差。目前對HRS治療的臨床研究大多樣本含量較低，方法學質量不高，證據強度不足，有待更多大樣本、多中心的高質量臨床試驗。

引用本文： 柳飛,李峻. 肝腎綜合征治療措施的臨床證據. 中國循證醫學雜志, 2007, 07(8): 618-622. doi: 復制

1.	Friedman S. Alcoholic liver disease, cirrhosis, and its major sequelae in: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa: Saunders, 2000: 804-812.
2.	Arroy V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology, 1996, 33(1): 164-173.
3.	Pere G, Monica G, Vicente A, et al. Hepatorenal syndrome. Lancet, 2003, 362: 1819-1827.
4.	Guyatt GH, Rennie D, Editors, The evidence-based medicine working group. Use’s guides to the medical literature: A manual for evidence-based clinical practice. AMA Press, Chicago, 2002.
5.	Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews: Reviews 2006 Issue 4.
6.	Cade R, Wagemaker H, Vogel S, et al. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med, 1987, 82(3): 427-438.
7.	Pomier LG, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology, 2003, 38(1): 238-243.
8.	Bruha R, Skupiny C, Balihar K, et al. Diagnostics and therapy of hepatorenal syndrome. Recommendations of the working group on portal hypertension of the Czech Hepatology Society and the J.E.Purkinje Czech Medical Society. Vnitr Lek, 2006, 52(6): 649-650.
9.	Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at low cost. Alim Pharm Ther, 2006, 23(1): 75-84.
10.	Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2004, 40(1): 55-64.
11.	Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology, 2002, 36(4 Pt 1): 941-948.
12.	Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology, 2002, 36(2): 374-380.
13.	Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenalsyndrome. J Hepatol, 2000, 33(1): 43-48.
14.	Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Am Fam Phy, 2006, 74(5): 767-776.
15.	Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastrol Hepatol, 2003, 18(2): 152-156.
16.	Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Euro J Gastroenterol Hepatol, 2002, 14(12): 1363-1368.
17.	Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J hepatology, 1998, 29(4): 565-570.
18.	Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol, 2002, 14(2): 153-158.
19.	Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology, 2002, 122(4): 923-930.
20.	Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27(1): 35-41.
21.	Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology, 1999, 29 (6): 1690-1697.
22.	Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl, 2000, 6(3): 287-289.
23.	Rossle M, SiegertetterV, HuberM, et al. The first decade of the transjugular intrahepatic portosystemic shunt ( TIPS) : state of the art. Liver, 1998, 11(1): 73-89.
24.	Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut, 2000, 47(2): 288-295.
25.	Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastrol, 2005, 100(4): 879-885.

1. Friedman S. Alcoholic liver disease, cirrhosis, and its major sequelae in: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa: Saunders, 2000: 804-812.
2. Arroy V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology, 1996, 33(1): 164-173.
3. Pere G, Monica G, Vicente A, et al. Hepatorenal syndrome. Lancet, 2003, 362: 1819-1827.
4. Guyatt GH, Rennie D, Editors, The evidence-based medicine working group. Use’s guides to the medical literature: A manual for evidence-based clinical practice. AMA Press, Chicago, 2002.
5. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews: Reviews 2006 Issue 4.
6. Cade R, Wagemaker H, Vogel S, et al. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med, 1987, 82(3): 427-438.
7. Pomier LG, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology, 2003, 38(1): 238-243.
8. Bruha R, Skupiny C, Balihar K, et al. Diagnostics and therapy of hepatorenal syndrome. Recommendations of the working group on portal hypertension of the Czech Hepatology Society and the J.E.Purkinje Czech Medical Society. Vnitr Lek, 2006, 52(6): 649-650.
9. Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at low cost. Alim Pharm Ther, 2006, 23(1): 75-84.
10. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2004, 40(1): 55-64.
11. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology, 2002, 36(4 Pt 1): 941-948.
12. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology, 2002, 36(2): 374-380.
13. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenalsyndrome. J Hepatol, 2000, 33(1): 43-48.
14. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Am Fam Phy, 2006, 74(5): 767-776.
15. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastrol Hepatol, 2003, 18(2): 152-156.
16. Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Euro J Gastroenterol Hepatol, 2002, 14(12): 1363-1368.
17. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J hepatology, 1998, 29(4): 565-570.
18. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol, 2002, 14(2): 153-158.
19. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology, 2002, 122(4): 923-930.
20. Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27(1): 35-41.
21. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology, 1999, 29 (6): 1690-1697.
22. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl, 2000, 6(3): 287-289.
23. Rossle M, SiegertetterV, HuberM, et al. The first decade of the transjugular intrahepatic portosystemic shunt ( TIPS) : state of the art. Liver, 1998, 11(1): 73-89.
24. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut, 2000, 47(2): 288-295.
25. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastrol, 2005, 100(4): 879-885.

《中國循證醫學雜志》

肝腎綜合征治療措施的臨床證據

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

肝腎綜合征治療措施的臨床證據

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料